![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Almac Group’s Diagnostics business unit announced its partnership with ArcherDx to provide FusionPlex® and VariantPlex NGS assays as part of their CDx partnership solutions.
ArcherDX, the leader in NGS-based fusion detection assays and software, has also approved Almac Diagnostics as a Certified Service Provider (CSP) of Archer® NGS assays. This agreement further establishes Almac Diagnostics as a trusted partner providing scientific and technological excellence globally.
Almac Diagnostics, the personalised medicine business unit of the Almac Group partners with Biopharma on the discovery, development and commercialisation of diagnostic tests including companion diagnostics. It also has an internal portfolio of both prognostic and predictive assays in development across a wide range of disease areas.
As an Archer Certified Service Provider, Almac Diagnostics will leverage their CLIA-certified lab to include Archer FusionPlex® and VariantPlex™ assays in their service offering. About becoming an Archer CSP, Michael Sloan, VP Commercial Operations at Almac Diagnostics, stated, “Archer assays will not only enable us to offer targeted sequencing panels across a wide range of malignancies, but they give us the ability to customise gene panels based on our partners’ needs.”
Jason Myers, PhD, CEO at ArcherDX, added “Almac Diagnostics has a strong support network as part of the Almac Group, which gives them the ability to provide clinical services beyond the UK. Because clinical development is a global need, we’re excited that Almac Diagnostics can offer ArcherDX NGS assays for international drug and CDx development and clinical support.”
About ArcherDX
ArcherDX addresses the bottlenecks associated with using NGS in translational research by offering a robust platform for targeted sequencing applications.By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry and easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by the Archer suite of bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.
About Almac Diagnostics
Almac Diagnostics is one of five business units operating under the ownership of the Almac Group. The global personalised medicine company is focused on the discovery, development and commercialisation of diagnostic tests including companion diagnostics. In addition, Almac Diagnostics has a pipeline of proprietary oncology based tests in development in therapeutic areas including breast, colon, ovarian, prostate and lung cancer.
About Almac Group
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo).https://www.almacgroup.com/diagnostics/
